FdaApplication
NDA 210922
Identifiers
- fda_app_no: NDA210922
Properties
| Property | Value |
|---|---|
| applicant_name | ALNYLAM PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2018-08-10 |
Revenue by product
ONPATTRO
| Period | Revenue |
|---|---|
| Q2 2026 | $18.5M |
| Q1 2026 | $20.5M |
| Q3 2025 | $39.1M |
| Q2 2025 | $52.5M |
| Q1 2025 | $49.5M |
| Q4 2024 | $56.1M |
| Q3 2024 | $50.3M |
| Q2 2024 | $77.2M |
| Q1 2024 | $69.2M |
| Q4 2023 | $79.0M |
| Q3 2023 | $81.6M |
| Q2 2023 | $91.5M |
| Q1 2023 | $102.5M |
| Q4 2022 | $122.2M |
| Q3 2022 | $144.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ONPATTRO | PATISIRAN SODIUM | EQ 10MG BASE/5ML (EQ 2MG BASE/ML) | SOLUTION;INTRAVENOUS |
1 product